Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)

PURPOSE: To investigate the efficacy and toxicity of cetuximab when added to radiochemotherapy for unresectable esophageal cancer. METHODS: This randomized phase 2 trial (clinicaltrials.gov, identifier NCT01787006) compared radiochemotherapy plus cetuximab (arm A) to radiochemotherapy (arm B) for un...

Descripción completa

Detalles Bibliográficos
Autores principales: Rades, Dirk, Bartscht, Tobias, Hunold, Peter, Schmidberger, Heinz, König, Laila, Debus, Jürgen, Belka, Claus, Homann, Nils, Spillner, Patrick, Petersen, Cordula, Kuhnt, Thomas, Fietkau, Rainer, Ridwelski, Karsten, Karcher-Kilian, Kerstin, Kranich, Anne, Männikkö, Sofia, Schild, Steven E., Maderer, Annett, Moehler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449950/
https://www.ncbi.nlm.nih.gov/pubmed/32533228
http://dx.doi.org/10.1007/s00066-020-01646-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449950/
https://www.ncbi.nlm.nih.gov/pubmed/32533228
http://dx.doi.org/10.1007/s00066-020-01646-4

Ejemplares similares